WeedMD (TSXV:WMD) announced the completed export of its cannabis genetics to Australia’s Medifarm.
As quoted in the press release:
“WeedMD has differentiated itself by proudly supplying more than 20 [percent] of the Canadian cannabis industry with its highly-regarded cannabis strains. Today, we are honoured to be one of the first Canadian LPs to welcome an international partner with the sale and export to Australia’s Medifarm,” said Keith Merker, CEO of WeedMD. “As trusted and proven cultivators in our respective markets, we’re thrilled to see selected WeedMD genetics enter Australia and provide Medifarm’s patients with our trusted cannabis strains.”
“Medifarm prides itself on the cultivation of exclusive cannabis genetics, supported by proven breeding programs used in university and hospital clinical trials for therapeutic use. WeedMD’s highly-regarded cannabis strains will help us bring Australians continued access to a diverse set of consistent, quality cannabis products,” said Edward Harris, Managing Director of Medifarm. “Ensuring that our patients have access to clinically-validated and cost-effective medicine for their therapeutic use is paramount for Medifarm. We are honoured to be making history alongside WeedMD – together we are amongst the very first LPs to secure respective export and import licenses for cannabis seeds.”